

Maribavir for treating refractory or resistant cytomegalovirus infection after transplant

Information for the public

Published: 18 January 2023

www.nice.org.uk

Maribavir (Livtency) is available on the NHS. It is a possible treatment for cytomegalovirus infection in adults who have had a stem cell transplant or organ transplant. It is only recommended if the infection comes back after, or does not respond well enough to, treatments such as ganciclovir, valganciclovir, cidofovir or foscarnet.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS website](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Anthony Nolan](#), 0303 303 0303
- [Leukaemia Care](#), 08088 010 444

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-4957-1